Panacea Life Sciences Holdings, Inc.

PLSH

US69810P1093

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 10:49:58 2024-05-30 EDT			5-day change	1st Jan Change
0.1484 ^USD	0.00%		0.00%	-1.07%

05-06	Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-01	Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Exactus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020

April 15, 2021 at 05:26 pm

Exactus, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced total revenue was USD 2.071 million compared to USD 345,680 a year ago. Operating loss was USD 10.554 million compared to USD 10.672 million a year ago. Net loss was USD 9.460 million compared to USD 9.481 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.31 a year ago.

Latest news about Panacea Life Sciences Holdings, Inc.

Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Panacea Life Sciences Holdings, Inc. completed the acquisition of N7 Enterprises, Inc.	23-10-04	CI
Panacea Life Sciences Holdings, Inc. entered into an Asset Purchase Agreement to acquire PÜR LIFE Medical, Inc.	23-10-01	CI
Panacea Life Sciences Holdings, Inc. completed the acquisition of Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp. for $7.8 million.	23-09-29	CI
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-15	CI
Panacea Life Sciences Holdings, Inc. entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.	23-08-01	CI
Panacea Life Sciences Holdings, Inc. agreed to acquire Nitro Kava & Kratom.	23-07-09	CI
Panacea Life Sciences Holdings, Inc. entered into agreements acquire 8 Retail Locations in the Tampa, Florida.	23-07-09	CI
Panacea Life Sciences Holdings, Inc. Distribution Division Signs Exclusive Distribution Agreement with QR Joy to Distribute U.S. Top Fume Disposable Vape Devices in the U.K	23-06-15	CI
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Panacea Life Sciences Holdings, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
Panacea Life Sciences Holdings, Inc. entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million.	23-01-22	CI
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Panacea Awarded Eight Nutraceutical Purchase Orders as It Expands Its U.S. Based Softgel Manufacturing Services into the Growing Health, Plant-Based Market	22-08-17	CI
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Panacea Life Sciences Holdings, Inc. Announces Resignation of Janice Nerger to Its Board of Directors	22-07-22	CI
Panacea Life Sciences Announces Launch of CBDA Oil Drops as Potential Complementary Treatment for Long COVID	22-07-14	CI
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
Panacea Life Sciences Holdings, Inc. Auditor Raises 'Going Concern' Doubt	22-03-30	CI
Panacea Life Sciences Holdings, Inc. Auditor Raises 'Going Concern' Doubt	21-12-16	CI
Panacea Life Sciences Holdings, Inc. announced that it expects to receive $1.1 million in funding from Lincoln Park Capital, LLC	21-11-17	CI

Chart Panacea Life Sciences Holdings, Inc.

Duration

Period

Chart Panacea Life Sciences Holdings, Inc.

More charts

Company Profile

Panacea Life Sciences Holdings, Inc. is a holding company organized as a plant-based natural health ingredient and product company. It specializes in the development, manufacturing, research, and distribution of products with natural health and wellness market segment for both humans and animals. The Companyâs subsidiary, Panacea Life Sciences, Inc. (PLS) is engaged in the production, distribution, research, and manufacturing of nutraceuticals, cannabinoids, mushrooms, kratom, and other natural, plant-based ingredients and products. The Company also offers natural remedies within its branded product lines for every aspect of life, including PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure, and PANA Life. It also operates 51,000 square foot current good manufacturing practice (cGMP) facility located in Golden, Colorado. The Company, through Panacea Life Sciences Holdings, Inc., manages six retail locations and a distribution center situated in the Tampa, Florida area.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PANACEA LIFE SCIENCES HOLDINGS, INC.	-1.07%	2.62M
ELI LILLY AND COMPANY	+39.82%	734B
NOVO NORDISK A/S	+31.53%	591B
JOHNSON & JOHNSON	-7.31%	350B
MERCK & CO., INC.	+14.23%	315B
ABBVIE INC.	+0.86%	276B
ASTRAZENECA PLC	+13.79%	238B
ROCHE HOLDING AG	-6.58%	204B
NOVARTIS AG	+8.33%	206B
AMGEN INC.	+4.51%	161B